Oncology Business Management

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.

Manmeet Singh Ahluwalia, MD, and his wife, Harneet Kaur Walia, MD, say that they learn from each other’s experiences and share in successes.

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.

The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.

A possible cause of some of the cost-related delays and nonadherence to treatment that patients with cancer and cancer survivors experience could be the time and effort they are forced to spend on administrative payment tasks related to their care.

A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.

As a result of the Affordable Care Act’s Medicaid expansion, positive trends are becoming apparent regarding mortality rates for patients with cancer living in the states that have adopted Medicaid expansion.

A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.

Investigators at Dana-Farber Cancer Institute in Boston, Massachusetts, developed a clinical outreach program combining diagnostic and patient navigation services.

CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them.

Here are 5 tips and tricks to help you shine when the spotlight is on you.

As artificial intelligence in cancer care continues to be better understood and refined, the number of potential clinical applications is rapidly expanding.

Prior authorization on cancer treatments is delaying patient care, affecting outcomes, and diverting providers from patient care according to results of a survey conducted by the Association for Clinical Oncology.

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Optimizing clinical pathways to address financial toxicities faced by patients with cancer requires a complex, multifaceted approach. However, even small in-practice changes may ease the financial burdens and improve outcomes.

Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice.

Maurie Markman, MD, elaborates on the need to take a closer look at the benchmarks used in clinical trial designs in oncology.

The publication of the objectively meaningful outcomes in high-impact peer-reviewed medical journals does not necessarily result in the observations being implemented into routine clinical care.